(Q37030838)

17 August 2017

1 reference

title

Carbapenems: a potent class of antibiotics (English)

1 reference

17 August 2017

main subject

carbapenem antibiotic

0 references

antibiotic

0 references

author name string

David P Nicolau

series ordinal

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

23-37

1 reference

Recent developments in carbapenems

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Appropriate and timely empirical antimicrobial treatment of icu infections--a role for carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Carbapenems in serious infections: a risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

The therapeutic challenge of Gram-negative sepsis: prolonging the lifespan of a scarce resource

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Ertapenem: a review of its use in the treatment of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Antibiotic rashes in children: a survey in a private practice setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Comparative tolerability of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

QT prolongation with antimicrobial agents: understanding the significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Probable vancomycin-induced neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Aminoglycosides for intra-abdominal infection: equal to the challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Is it safe to use carbapenems in patients with a history of allergy to penicillin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Of Pseudomonas, porins, pumps and carbapenems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

In vitro antimicrobial activity of doripenem, a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Seizures in the critically ill: the role of imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Ertapenem, the first of a new group of carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Activity of ertapenem against Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Properties and potential of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.1.23

21 January 2018

Identifiers

DOI

10.1517/14656566.9.1.23

1 reference

17 August 2017

1 reference